Skip to main content
. 2022 Feb 18;9:813550. doi: 10.3389/fcvm.2022.813550

Table 2.

Changes of standard coagulation parameters, coagulation factors, red blood cells and platelet count during exposure to moderate, high and extreme altitudes (16 studies, n = 388).

Authors Maximum altitude [m] Participants
M/F, age [years]
Type of
physical activity
Maximum duration Parameter Maximum change Level of
significance
Active Passive
Moderate altitude
Bendz et al. (17) 2400
(simulated)
20 M
20–40
Activities of daily living 8 h F.VII (U/L) +17% p = 0.008
F.VII AG (%) −5% p = 0.003
PTF 1+2 (nM/L) +250% p = 0.008
TAT complex (μg/L) +820% p = 0.04
High altitude
Bartsch et al. (16) 4559
(terrestrial)
11 M
22–55
Climbing 5 days Fibrinogen (g/L) +23% p < 0.025
Kicken et al. (20) 3883
(terrestrial)
11 M, 7 F
(only 17 results)
21–50
Ascent by car and cable car 6 days Hb (g/L) +3% p = 0.004
Hct (L/L) +9% p = 0.0002
F.VIII (%) +8% p = 0.0075
Kicken et al. (21) 3375
(terrestrial)
6 M
18–48
Vigorous exercise 6 days Hb (g/L) +24% p < 0.0001
vWF (%) +53% p = 0.0002
vWF (%) +59% p = 0.0002
F.VIII (%) +43% p = 0.0009
Lehmann et al. (22) 4559
(terrestrial)
10b Climbing 18 h PLT count (x 103/μL) −23% p ≤ 0.001
Maher et al. (23) 4400
(simulated)
8 M
22 ± 1
Activities of daily living 48 h Hct (L/L)c +4% p < 0.05
PTT (sec)c −370%+ p < 0.05
Fibrinogen (g/L)c +79% p < 0.01
F.VIII (%)c −32% p < 0.02
Martin et al. (24) 5300
(terrestial)
12 M, 5 F
34.0 ± 9.8
Climbing 17 days Hb (g/L) +20% p < 0.01
Modesti et at. (25) 5400
(terrestrial)
25 M, 6 F
24–62
Climbing 19 days Hct (L/L) +19% p < 0.001
Ninivaggi et al. (26) 3900
(terrestial)
14 M,16 F
28-32
7 M, 8 F
Climbing
7 M, 8 F
Ascent by cable car
8 days Active: vWF (%) +21% p < 0.05
Active: F.VIII (%) +25%a p < 0.05
Passive: vWF (%) +5%+ p < 0.05
Passive: F.VIII (%) +12%+ p < 0.05
Rocke et al. (28) 5200
(terrestrial)
37 M, 26 F
26.4 ± 3.9
G1: n = 41
G2: n = 22
Ascent by plane and car 7 days G1: Hb (g/L) +12% p < 0.005
G2: Hb (g/L) +7% p < 0.0001
G1: Hct (L/L) +14% p < 0.005
G2: Hct (L/L) +17% p < 0.0001
G2: Fibrinogen (g/L) +27% p < 0.001
G1: PLT count (x 103/μL) +19% p < 0.005
G1: PLT count (x 103/μL) +31% p < 0.0001
Schaber et al. (29) 4500
(simulated)
21 M, 16 F
19–42
Free movement 12 h PT (%) +7% p = 0.029
Singh et al. (33) 3505
(terrestial)
16 M
20–42
Free movement 3 days Fibrinogen −20% p < 0.01
Extreme altitude
Albrecht and Albrecht (14) 6200
(terrestrial)
G2 (placebo)
11d
(Age and sex NG)
Climbing 35 days PT (%) −46% p < 0.001
Andrew et al. (15) 7625
(simulated)
8 M
21–31
Incremental cycling 40 days F.VIII:Complex (%) +40% p < 0.05
Doughty et al. (19) 5700
(terrestrial)
6 Me Climbing 48 days Hb (g/L) +44% NG
Bleeding time +81% NG
Pichler Hefti et al. (27) 6865
(terrestrial)
G1 (fast ascent):
15 M, 3 F
G2 (slow ascent):
12 M, 4 F
46 (median)
Climbing 22 days PT (%) +16%+ p < 0.001
aPTT (sec) +38%+ p < 0.001
APC-R −16% p < 0.001
G1: vWF-RCo (%) −24%+ p < 0.001
G2: vWF-RCo (%) −34%+ p < 0.001

F, female; M, male; AG, antigen; APC-R, activated protein C resistance; aPTT, activated partial thromboplastin time; G1, group 1; G2, group 2; Hb, hemoglobin; Hct, hematocrit; μL, microliter; NG, not given; PLT, platelet; PT, prothrombin time; sec, second; vWF-Rco, von Willebrand factor-ristocetin cofactor activity. All p-values reflect intragroup comparisons unless otherwise indicated.

a

At 2045 m.

b

10 subjects out of 36 M and 4 F, aged 40 ± 9 yrs.

c

Results after 1 h at altitude.

d

Results after 1 h at altitude.

e

Age and sex not reported.

f

Age not reported.

+

Estimated from figures.

Reported in the original study.